A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours - Not applicable

Study identifier:D5330C00017

ClinicalTrials.gov identifier:NCT05514132

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Medical condition

Advanced Solid Tumours

Phase

Phase 1

Healthy volunteers

No

Study drug

Ceralasertib, Durvalumab

Sex

All

Actual Enrollment

14

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 23 Sept 2022
Primary Completion Date: 20 Oct 2023
Estimated Study Completion Date: 01 Apr 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria